NEA (NKTX) drops below 5% ownership in latest Schedule 13D/A filing
New Enterprise Associates (NEA) and its affiliated entities have filed an Amendment No. 3 to their Schedule 13D for Nkarta, Inc. (NKTX), indicating their beneficial ownership has fallen to 4.9% of outstanding shares. This change is primarily due to an increase in Nkarta's total shares outstanding rather than recent transactions by NEA. The filing clarifies that NEA holds its stake for investment purposes and has no current plans for corporate actions or changes to Nkarta's management.
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m
Nkarta's market capitalization has dropped to US$201m. Insiders, particularly CEO Paul Hastings, sold US$69k worth of stock at an average price of US$2.06 per share over the past year, before the recent 11% stock price drop. The article notes low insider ownership and a lack of recent insider buying, which it considers unenthusiastic signals for the company.
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m
Insiders at Nkarta, Inc. sold US$69k worth of stock over the past year at an average price of US$2.06, with the largest sale made by CEO Paul Hastings below the current stock price. The company's market cap recently fell by US$24m (11%), but insiders avoided these losses due to their earlier sales. The article notes the low insider ownership (US$820k) and absence of recent insider buying as potentially discouraging signals for investors.
Nkarta, Inc. Stock 12‑Month Price Target Raised to $11.8, Implies 260% Upside
The average 12-month price target for Nkarta, Inc. (NKTX) stock has been raised from $11.6 to $11.8 by 5 analysts, with individual forecasts ranging from $9 to $16 per share. This new target suggests a potential upside of approximately 260% from the May 12 closing price. The consensus rating for Nkarta, Inc. remains a "Buy" from all 5 covering analysts.
Nkarta Price Target Maintained With a $11.00/Share by Needham
Needham has maintained its price target for Nkarta (NKTX) at $11.00 per share. This financial update follows the company's third-quarter report, suggesting ongoing analyst confidence in the stock's valuation. The article also briefly mentioned Unity Software's fourth-quarter financial results.
Nkarta (NKTX) Q1 2026 results: NKX019 trial progress and cash runway into 2029
Nkarta (NKTX) reported its Q1 2026 financial results, showing a narrower net loss of $27.8 million and extending its cash runway into 2029 with $266.7 million in cash and equivalents. The company also provided clinical updates on its NKX019 autoimmune program, including FDA agreement for outpatient dosing and expansion to include rheumatoid arthritis in its Ntrust-2 trial, with initial clinical data expected in 2026. These advancements aim to broaden patient access and accelerate trial progress for its CAR-NK cell therapy.
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Nkarta, Inc. reported its first-quarter 2026 financial results, highlighting ongoing enrollment in its NKX019 clinical trials (Ntrust-1 and Ntrust-2) for autoimmune diseases. The company announced regulatory agreement for expanding NKX019 into community-based, outpatient settings and expects initial clinical data from these trials to be presented at a medical meeting later in 2026. Nkarta's cash balance of $266.7 million as of March 31, 2026, is projected to fund operations into 2029.
Nkarta Inc NKTX
This page provides real-time market data for Nkarta Inc (NKTX), including its current stock price, recent performance, and market capitalization. It also offers sections for financials, discussions, and analysis, along with general tools for investment research provided by TradingKey. The platform emphasizes risk warnings regarding investment products and third-party analysis.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts
Analysts have issued an average "Hold" rating for Nkarta, Inc. (NASDAQ:NKTX), with a consensus twelve-month price target of $11.33. The clinical-stage biotechnology company recently missed its quarterly EPS estimates, reporting -$0.37 against an expected -$0.32, and shares are currently trading around $2.77. Institutional investors hold approximately 80.54% of the company's stock.
[ARS] Nkarta, Inc. SEC Filing
This article reports on Nkarta, Inc.'s SEC filing identified as ARS, with a low impact and neutral sentiment. The filing occurred on April 23, 2026, at 04:42 PM, and the document is available in PDF format via SEC EDGAR. Nkarta, Inc. (NKTX) is a biotechnology company with a market cap of $236.68 million.
Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting
Nkarta, Inc. will hold a virtual annual meeting on June 10, 2026, where stockholders will vote on several key proposals. These include the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, an advisory vote on executive compensation, and the frequency of future say-on-pay votes, with the board recommending an annual frequency. The proxy statement details executive and director compensation, including CEO total compensation of $2,978,038 in 2025, and outlines the company's governance practices.
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Nkarta, Inc. has reached an agreement with the FDA for key changes to its Ntrust-1 and Ntrust-2 clinical trials for NKX019, an investigational CAR-NK cell therapy for autoimmune diseases. These changes will allow for outpatient dosing, significantly reducing patient burden and expanding access to community rheumatology centers. Additionally, the protocol amendments enable the option to redose patients and will add a rheumatoid arthritis cohort to the Ntrust-2 study.
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Stifel has reiterated its Buy rating on Nkarta (NKTX.US) and maintained a target price of $11. This indicates a continued positive outlook from the financial firm regarding the company's stock performance.
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Needham has reaffirmed its Buy rating for Nkarta (NKTX.US), maintaining a target price of $11. This indicates the firm's continued confidence in the company's prospects. Investors may view this sustained recommendation as a positive signal for Nkarta's stock.
Nkarta targets 2-hour monitoring, not overnight stays, in cell therapy trials
Nkarta has reached an agreement with the FDA to amend protocols for its Ntrust-1 and Ntrust-2 clinical trials, allowing for outpatient dosing of NKX019 and reducing post-dose monitoring from 24 hours to 2 hours. This change aims to reduce patient burden and expand access to community rheumatology centers. The amendments also include an option to re-dose participants and will add a rheumatoid arthritis cohort to Ntrust-2, with initial data expected this year.
Nkarta Announces FDA Agreement on Outpatient Dosing of
Nkarta, Inc. has reached an agreement with the FDA for key changes to its Ntrust-1 and Ntrust-2 clinical trials, allowing outpatient administration of NKX019 and reducing patient burden. This amendment will also enable the addition of a rheumatoid arthritis cohort to the Ntrust-2 study and allow for re-dosing of patients. These changes aim to expand access to community rheumatology centers and optimize treatment responses.
Nkarta Announces FDA Agreement on Outpatient Dosing of
Nkarta, Inc. announced FDA agreement on key changes to its Ntrust-1 and Ntrust-2 clinical trials for NKX019, an investigational CAR-NK cell therapy for autoimmune diseases. These amendments will enable outpatient administration, reducing patient burden and expanding access to community rheumatology centers. The changes also include an option to redose patients and the addition of a rheumatoid arthritis cohort to the Ntrust-2 study, with initial data expected this year.
Nkarta Announces FDA Agreement on Outpatient Dosing of
Nkarta, Inc. has reached an agreement with the FDA for key changes to its Ntrust-1 and Ntrust-2 clinical trials, enabling outpatient administration of NKX019 and reducing patient burden. The amendments also allow for re-dosing patients and will add a rheumatoid arthritis cohort to the Ntrust-2 study, expanding access and optimizing treatment responses. Initial data from these trials is expected to be presented at a medical meeting later this year.
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a virtual panel discussion on "Cell Therapy in Autoimmune: State of the Art and What Comes Next," and President Nadir Mahmood will provide updates on the company’s investigational CAR-NK cell therapy. A webcast of the fireside chat will be available on Nkarta's investor website.
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a virtual panel discussion on cell therapy in autoimmune diseases, while President Nadir Mahmood will lead a fireside chat discussing updates on the company's investigational CAR-NK cell therapy. A webcast of the fireside chat will be available on Nkarta's website.
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies for autoimmune diseases, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a panel discussion on "Cell Therapy in Autoimmune" on April 15, and later that day, President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy in a fireside chat. A webcast of the fireside chat will be available on Nkarta's investor relations website.
Nkarta leaders to discuss autoimmune cell therapy at Needham event
Nkarta (Nasdaq: NKTX) announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel discussion on cell therapy in autoimmune diseases, and President Nadir Mahmood will deliver a fireside chat providing updates on the company's investigational CAR-NK therapy for B cell-mediated autoimmune diseases. A webcast of the fireside chat will be available on Nkarta's Investors website and archived for approximately 90 days.
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 9, 2026. CEO Paul Hastings will join a virtual panel discussion on "Cell Therapy in Autoimmune: State of the Art and What Comes Next" on April 15, and later the same day, President Nadir Mahmood will provide updates on the company's investigational CAR-NK cell therapy during a fireside chat. A webcast of the fireside chat will be available on the Investors section of Nkarta’s website.
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Hold" by Analysts
Nkarta, Inc. (NASDAQ:NKTX) has an average "Hold" recommendation from five brokerages, with an average 12-month price target of $11.33. The company recently missed its EPS estimates and its CEO, Paul J. Hastings, sold 26,046 shares in January. Institutional investors hold a significant portion of the stock, while its shares currently trade around $2.32.
[EFFECT] Nkarta, Inc. SEC Filing
This article reports on an SEC filing by Nkarta, Inc. (NKTX) for a Form EFFECT, which became effective on April 3, 2026, at 4:00 P.M. The filing is identified as an S-3 form related to shelf registration. The article also provides Nkarta's stock overview, recent news, and other SEC filings.
Nkarta (NASDAQ: NKTX) launches $100M ATM shelf via Stifel as sales agent
Nkarta, Inc. (NASDAQ: NKTX) has filed a prospectus to offer up to $100 million in common stock through an "at-the-market" (ATM) program, with Stifel, Nicolaus & Company, Incorporated acting as the sales agent. The offering allows Nkarta to sell shares at current market prices, providing flexibility for capital raises. Proceeds from the offering are intended for research, development, manufacturing of product candidates, advancing its NK cell therapy platform, increasing working capital, funding capital expenditures, and general corporate purposes.
NKTX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Nkarta Inc (NKTX), showing a "Strong Buy" consensus based on various technical indicators and moving averages. Key metrics like RSI, MACD, and support/resistance levels are detailed, along with frequently asked questions about the stock's current technical outlook.
NKTX PE Ratio & Valuation, Is NKTX Overvalued
Nkarta Inc (NKTX) is currently considered to be in the "Fair zone" based on its forward PS ratio of 0.00 compared to its five-year average of -3.85. The article details various valuation metrics for NKTX, including its Price-to-Book ratio, Free Cash Flow yield, and a comparison of its P/S ratio against competitor averages, noting that a robust revenue growth figure is needed to justify its premium.
Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho
Mizuho analysts have lowered their price target for Nkarta (NASDAQ:NKTX) from $14.00 to $12.00, while maintaining an "outperform" rating. This new target suggests a potential upside of approximately 467.91% from Nkarta's previous closing price. The company reported negative earnings per share (EPS) of -$0.37, missing analyst estimates, and currently holds a consensus "Hold" rating among analysts with an average target price of $11.33.
HC Wainwright Forecasts Nkarta's Q1 Earnings (NASDAQ:NKTX)
HC Wainwright has revised its Q1 2026 earnings per share estimate for Nkarta (NASDAQ:NKTX) down to ($0.40) from ($0.34), also lowering forecasts for subsequent quarters and fiscal years up to 2030. This adjustment suggests a weaker near-term outlook due to anticipated higher costs or extended development timelines. Despite the revised estimates and a mixed analyst sentiment, Nkarta's stock currently holds a consensus "Hold" rating with an average price target of $12.00, significantly higher than its current trading price of $2.06.
Nkarta (NASDAQ:NKTX) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded Nkarta (NASDAQ:NKTX) from a "hold" to a "sell" rating, despite the broader Street consensus remaining a "Hold" with an average target price of $12.00. The downgrade follows Nkarta reporting a Q1 EPS of ($0.37), missing estimates, and comes after CEO Paul J. Hastings sold a portion of his shares. The biotechnology company, specializing in NK cell therapies for cancer, currently trades near $2.06 with a market cap of approximately $153 million, and its stock has experienced a 52-week range of $1.42–$2.81.
TD Cowen Maintains Nkarta(NKTX.US) With Buy Rating
TD Cowen has reiterated its Buy rating on Nkarta (NKTX.US). This endorsement suggests the firm's continued confidence in the company's stock performance. Investors will likely view this as a positive signal regarding Nkarta's outlook.
Nkarta Launches $100 Million At-the-Market Stock Offering
Nkarta Inc. has initiated an at-the-market equity offering of up to $100 million of its common stock through a sales agreement with Stifel, Nicolaus & Company. This offering, detailed in an S-3 shelf registration, provides Nkarta with flexible access to capital to support its business needs. Analysts currently rate NKTX stock as a Hold with a $2.00 price target, while Spark, TipRanks' AI Analyst, views it as Neutral due to weak financial performance and bearish technical indicators.
NKTX (Nkarta) PB Ratio : 0.51 (As of Mar. 26, 2026)
This article from GuruFocus.com analyzes Nkarta Inc.'s (NKTX) Price-to-Book (PB) Ratio, which stands at 0.49 as of March 27, 2026. The ratio is significantly lower than the Biotechnology industry median, indicating a potentially undervalued stock relative to its assets, though the company also carries 3 warning signs. The article explains the PB Ratio calculation, its historical trends for Nkarta, and compares it to industry peers.
Stifel reiterates Nkarta stock rating on trial enrollment progress
Stifel maintained its Buy rating and an $11.00 price target on Nkarta Inc. (NASDAQ:NKTX) shares. The firm is encouraged by the patient enrollment progress in the Ntrust-1/2 trials for NKX019 in autoimmune diseases, although uncertainties remain regarding the magnitude and duration of future data disclosures. Stifel believes data showing deep B cell depletion and subsequent healthy B cell reconstitution will improve visibility into clinical outcomes.
Nkarta Launches $100 Million At-the-Market Stock Offering
Nkarta (NKTX) has launched a $100 million at-the-market (ATM) stock offering with Stifel, Nicolaus & Company to provide flexible access to equity capital. This offering allows Nkarta to raise funds opportunistically to support its business operations and clinical development programs. The company's stock currently holds a "Hold" rating from analysts with a $2.00 price target, while TipRanks' AI Analyst, Spark, assesses NKTX as Neutral due to weak financial performance and bearish technical indicators.
Nkarta launches $100M at-the-market equity program with Stifel
Nkarta (NKTX) has initiated an at-the-market offering agreement with Stifel, allowing the company to sell up to $100 million of common stock. Nkarta will maintain control over the offering parameters, including timing and pricing, to manage dilution and the influx of proceeds. Stifel will act as the sales agent, utilizing various trading markets and potentially earning up to a 3% commission on gross proceeds.
Nkarta (NASDAQ: NKTX) launches $100M at-the-market stock sale plan
Nkarta (NASDAQ: NKTX) has initiated an at-the-market stock offering program, allowing it to sell up to $100 million in common stock through Stifel, Nicolaus & Company as its sales agent. The company will retain control over the sale parameters, including timing, volume, and minimum prices, and will pay Stifel a commission of up to 3% of the gross proceeds. This program is being executed under Nkarta’s existing Form S-3 registration statement and an accompanying prospectus supplement filed with the SEC.
Nkarta (NASDAQ: NKTX) launches $100M at-the-market program via $350M shelf
Nkarta, Inc. (NASDAQ: NKTX) has filed an S-3 shelf registration statement for up to $350 million in various securities, which includes an at-the-market (ATM) program of up to $100 million for common stock through Stifel, Nicolaus & Company, Incorporated. The proceeds from sales through this ATM program will be used for general corporate purposes, including funding research, development, and manufacturing of its product candidates, and increasing working capital. As of March 18, 2026, the company had 74,290,521 shares of common stock issued and outstanding.
Nkarta 2025 10-K: Net loss $104.1M, EPS $(1.41)
Nkarta reported a net loss of $104.1 million for the year ended December 31, 2025, with an EPS of $(1.41), and an operating loss of $122.0 million. The company implemented cost containment measures, workforce reductions, and strategically prioritized its NKX019 program, including advancing clinical trials and optimizing its manufacturing model. Nkarta expects its current cash and investments to support operations for at least 12 months, with plans to raise additional capital.
Nkarta (NASDAQ: NKTX) reports 2025 loss and extends cash runway to 2029
Nkarta, Inc. reported its fourth quarter and full-year 2025 financial results, showing a net loss of $104.1 million for the year. The company's cash, cash equivalents, and investments totaled $295.1 million as of December 31, 2025, which is projected to fund operations into 2029. Nkarta also highlighted continued clinical progress for its NKX019 autoimmune program, with initial clinical data expected to be presented at a medical conference in 2026.
Nkarta (NASDAQ:NKTX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS
Nkarta (NASDAQ:NKTX) reported quarterly earnings of ($0.37) per share, missing consensus estimates by $0.05. Despite missing expectations, the stock rose by 3.9% to $2.13. Insider transactions included CEO Paul J. Hastings selling shares, while institutional investors have adjusted their holdings.
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Nkarta, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting advancements in its NKX019 clinical program for autoimmune diseases. The company increased the dose escalation for NKX019 and anticipates presenting initial clinical data from its Ntrust-1 and Ntrust-2 trials at a medical conference in 2026. Nkarta's cash balance of $295.1 million as of December 31, 2025, is projected to fund operations into 2029.
Nkarta (NKTX) to Release Earnings on Tuesday
Nkarta (NASDAQ:NKTX) is scheduled to release its Q4 2025 earnings before the market opens on Tuesday, March 31st, with analysts forecasting a loss of ($0.32) per share. The stock currently trades around $2.18, within a 52-week range of $1.31–$2.81, and has a market capitalization of $154.85 million. Insider selling by CEO Paul J. Hastings and significant institutional holdings activity have been noted, while analysts maintain a "Moderate Buy" consensus with a price target of $13.25.
If You Invested $1,000 in Nkarta, Inc. (NKTX)
This article analyzes the historical performance of investing $1,000 in Nkarta, Inc. (NKTX) over various periods, showing significant losses over 5 and 10 years but a gain over the last year. It also provides a detailed overview of Nkarta, Inc.'s focus on engineered natural killer (NK) cell therapies for autoimmune diseases, highlighting its key therapeutic candidate NKX019 and ongoing clinical trials. The company's scientific rationale, regulatory status, and risk considerations are discussed to offer a comprehensive profile for potential investors.
Nkarta Inc expected to post a loss of 32 cents a share - Earnings Preview
Nkarta Inc (NKTX) is projected to report an earnings loss of 32 cents per share. This financial forecast comes as part of an earnings preview. The information was provided by Reuters and Refinitiv.
NKTX Q4'25 Earnings: EPS estimate is (0.31) USD
Nkarta, Inc. (NKTX) is scheduled to release its Q4'25 earnings on March 19, with an estimated EPS of (0.31) USD and revenue of 0 USD. The article provides a table of past and estimated revenue and EPS figures, highlighting EPS surprises.
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Nkarta, Inc. (NASDAQ:NKTX) has received a consensus "Moderate Buy" rating from six brokerages, with an average one-year price target of $13.25 significantly above its current trading price. The company's shares opened at $2.43, down about 5.4%, giving it a market cap of $172.6 million. Insider Paul J. Hastings recently sold 26,046 shares, representing a 6.26% reduction in his position, while institutional investors and hedge funds hold a substantial 80.54% of the stock.
NKTX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive overview of Nkarta, Inc.'s (NKTX) financial statements, including income statements, balance sheets, and cash flow statements, derived from SEC filings. It highlights key financial metrics for fiscal year 2024, such as $0 revenue, -$108.8M net income, and a low Piotroski F-Score, indicating weak financial health. The report also details the company's negative free cash flow, operating cash flow, and an estimated cash runway of approximately 3 months.
Nkarta to Participate in March Investor Conferences
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company focused on developing NK cell therapies for autoimmune diseases, announced its participation in two investor conferences in March 2026. The company will hold fireside chats at the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference. Webcasts of both events will be available on Nkarta's website.
